



FLORIDA VASCULAR SOCIETY

Celiac Peri-ganglionic Fibrosis Assessment in Median Arcuate Ligament Syndrome: Correlation with Post-operative Clinical Outcomes

Adeeb Jilati, MD

Research trainee

Division of Vascular and Endovascular Surgery

Mayo Clinic, Florida

Orlando, FL – April 23-26




DISCLOSURES

- None


BACKGROUND

- Median arcuate ligament syndrome (MALS) is a condition in which the median arcuate ligament (MAL) compresses the celiac axis region.
- MALS is historically related to the compression of the celiac artery.
- However, recent evidence showed that chronic compression of the celiac plexus may be the primary driver of symptoms.



PRESENTATION

- This compression leads to a constellation of foregut ischemia-like symptoms, including:
 - Postprandial abdominal pain
 - Unintentional weight loss
 - Food fear
 - Nausea and vomiting
- } MALS triad
- These symptoms may reflect a combination of vascular insufficiency and/or neurogenic irritation rather than arterial narrowing alone.
 - This helps explain why imaging severity does not always match symptom severity.



STUDY RATIONALE

- MALS pathophysiology remains poorly understood.
- Recent evidence shows inflammation and fibrosis in celiac ganglia, but comprehensive histopathology data is still limited.
- We therefore evaluated whether the degree of fibrosis around the celiac ganglion correlates with postoperative improvement in symptoms after MAL release and celiac ganglionectomy.
- Aim: To determine whether the degree of fibrosis around the celiac ganglion correlates with symptoms severity.

METHODS

- A retrospective single-institution review in patients who underwent MAL release combined with celiac ganglionectomy.
- Time period: 2015-2024.
- Tissue analysis:
 - Resected celiac ganglions were formalin-fixed, H&E-stained, and digitally scanned.
 - Assessed the presence of ganglion cells.
 - Thickness of peri-ganglionic fibrotic tissue was measured digitally.
- Postoperative clinical outcomes, including abdominal pain and nausea improvement, were recorded and correlated with fibrosis measurements.

RESULTS

30

Total Patients
Diagnosed with
MALS




70%

Had Fibrosis
Present in Specimens

Peri-ganglionic
fibrosis thickness

Mean: 0.21 (0.14)

**Median: 0.18
(0.11, 0.26)**



RESULTS

	No Fibrosis (N=9)	Fibrosis (N=21)	p value
Age			0.469
- Mean (SD)	42.111 (17.864)	36.952 (15.028)	
- Median (Q1, Q3)	44.000 (28.000, 51.000)	32.000 (24.000, 48.000)	
BMI			0.03
- Mean (SD)	20.811 (1.837)	23.723 (4.048)	
- Median (Q1, Q3)	20.700 (19.900, 20.900)	23.278 (21.000, 26.253)	
Hospital LOS			0.398
- Mean (SD)	2.000 (1.581)	1.619 (1.071)	
- Median (Q1, Q3)	2.000 (1.000, 2.000)	1.000 (1.000, 2.000)	
Last follow up (days)			0.7
- Mean (SD)	75.778 (72.729)	112.905 (165.849)	
- Median (Q1, Q3)	40.000 (29.000, 88.000)	34.000 (28.000, 110.000)	
Sex			0.593
- Female	7 (77.8%)	18 (85.7%)	
- Male	2 (22.2%)	3 (14.3%)	
Previous GI surgery	3 (33.3%)	7 (33.3%)	1
Depression	3 (33.3%)	9 (42.9%)	0.626
Anxiety	3 (33.3%)	8 (38.1%)	0.804

RESULTS

	No Fibrosis (N=9)	Fibrosis (N=21)	p value
Abd Pain postprandial	8 (88.9%)	16 (76.2%)	0.426
Abd pain exertional	2 (22.2%)	5 (23.8%)	0.925
Abd Pain unprovoked	6 (66.7%)	10 (47.6%)	0.338
Nausea	4 (44.4%)	12 (57.1%)	0.523
Vomiting	1 (11.1%)	2 (9.5%)	0.894
Constipation	2 (22.2%)	2 (9.5%)	0.348
Diarrhea	1 (11.1%)	2 (9.5%)	0.894
Weight loss	6 (66.7%)	16 (76.2%)	0.589
GI screening	9 (100.0%)	20 (95.2%)	0.506

RESULTS

	No Fibrosis (N=9)	Fibrosis (N=21)	p value
Abd Pain Resolution			0.257
• Worsened	1 (11.1%)	0 (0.0%)	
• unchanged	2 (22.2%)	6 (28.6%)	
• improved	5 (55.6%)	8 (38.1%)	
• resolved	1 (11.1%)	7 (33.3%)	
Nausea Resolution			0.605
• Worsened	1 (11.1%)	1 (4.8%)	
• unchanged	2 (22.2%)	10 (47.6%)	
• improved	4 (44.4%)	7 (33.3%)	
• resolved	2 (22.2%)	3 (14.3%)	
Narcotic use at F.U			0.533
• None	6 (66.6%)	15 (71.4%)	
• Decreased	0 (0.0%)	1 (4.8%)	
• Unchanged	1 (11.1%)	3 (14.3%)	
• Increased	2 (22.2%)	2 (9.5%)	

RESULTS

Abdominal Pain Improvement	No (N=9)	Yes (N=21)	p value
Measurement of Fibrosis			0.281
Mean (SD)	0.23 (0.12)	0.21 (0.20)	
Median (Q1, Q3)	0.19 (0.16, 0.30)	0.16 (0.10, 0.30)	
Nausea Improvement	No (N=14)	Yes (N=16)	p value
Measurement of Fibrosis			0.839
Mean (SD)	0.20 (0.12)	0.23 (0.18)	
Median (Q1, Q3)	0.16 (0.12, 0.23)	0.19 (0.10, 0.25)	

LIMITATIONS

- Retrospective design.
- Limited cohort.
- Variable specimen quality due to difficulty in reliably identifying celiac ganglion tissue intraoperatively.

CONCLUSION

- Degree of celiac peri-ganglionic fibrosis showed no correlation with postoperative outcomes.
- Similar symptom relief achieved regardless of fibrosis extent.
- Fibrosis alone did not explain clinical presentation or postoperative outcomes in MALS.



FLORIDA VASCULAR SOCIETY

THANK YOU

Division of Vascular and Endovascular Surgery.

Houssam Farres, MD.
Young Erben, MD.
Christopher Jacobs, MD.

Camilo Polania, MD.
Camila Esquetini, MD.
Adeeb Jilati, MD.
Diego Sanchez, MD.
Ekin Inal, MD.

Orlando, FL – April 23-26

